NDC product
GARDASIL 9
NDC 0006-4121 · Merck Sharp & Dohme LLC
Key facts
| Product NDC | 0006-4121 |
|---|---|
| Proprietary name | GARDASIL 9 |
| Nonproprietary name | Human Papillomavirus 9-valent Vaccine, Recombinant |
| Substances | HUMAN PAPILLOMAVIRUS TYPE 6 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 11 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 16 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 18 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 31 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 33 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 45 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 52 L1 CAPSID PROTEIN ANTIGEN, HUMAN PAPILLOMAVIRUS TYPE 58 L1 CAPSID PROTEIN ANTIGEN |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Labeler | Merck Sharp & Dohme LLC |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA125508 |
| Pharmacologic classes | Actively Acquired Immunity [PE], Inactivated Human Papillomavirus Vaccine [EPC], Papillomavirus Vaccines [CS], Vaccines, Inactivated [CS] |
| Marketing start | Dec 10, 2014 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: